Prescription Drug Recall: Atorvastatin Calcium Tablets for Manufacturing Deviations
Accord Healthcare is recalling Atorvastatin Calcium 10 mg tablets distributed in the United States, Puerto Rico, and Canada following FDA inspection findings of manufacturing deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses, hospitalizations, or injuries. The hazard is theoretical manufacturing deviations without a named specific quality defect. Per the editorial rubric, when no illnesses are reported and the hazard is theoretical, the score is at most 3. This precautionary recall warrants a Moderate classification.
Plain-English summary
Accord Healthcare, Inc. is recalling Atorvastatin Calcium Tablets USP, 10 mg, Rx Only, distributed in the United States, Puerto Rico, and Canada. A total of 256,106 bottles are affected, covering multiple batch numbers with expiration dates between March 31, 2023 and June 30, 2024.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations. CGMP violations indicate that the manufacturer's quality control and production processes did not meet FDA regulatory standards for pharmaceutical manufacturing.
Consumers holding affected bottles of Atorvastatin Calcium 10 mg should verify their batch number against the recall records and contact their pharmacy or healthcare provider for guidance on obtaining replacement medication.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a)R2100455
- Exp. Date 3/31/2023
- R2200274
- Exp. Date 1/31/2024
- R2200700
- Exp. Date 5/31/2024
- b) R2101342
- R2101343
- R2101476
- Exp. Date 9/30/2023
- R2101364
- R2101365
- R2101366
- R2101367
- Exp. Date 10/31/2023
- R2101612
- R2101613
- R2101614
- Exp. Date 11/30/2023
- R2200222
UPCs (2)
- 316729044158
- 316729044172
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin Calcium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin Calcium tablets recalled nationwide for failed dissolution specifications
FDA (Drugs) · 2025-10-22
- HighAtorvastatin Calcium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin Calcium Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27